Spanish Researchers Show Photoswitchable Drug Candidates Restore Vision
Researchers in Spain have developed photoswitchable small-molecule compounds that can restore visual function in animal models of retinal degeneration. This noninvasive approach aims to bypass the need for gene therapy or implants by reactivating existing retinal circuitry.
Why it matters
This breakthrough offers a potential future treatment for millions suffering from conditions like age-related macular degeneration without the risks associated with invasive surgeries.
Researchers led by the Institute for Bioengineering of Catalonia (IBEC) in Barcelona, Spain, have developed a new class of photoswitchable small-molecule compounds that restored vision-related behaviors in animal models of retinal degeneration, advancing a noninvasive approach to vision restoration that does not require gene therapy or implanted devices.
The findings, published in the Journal of the American Chemical Society, and detailed in an article on the IBEC website, describe a family of photopharmacological compounds known as prosthe6, which are designed to mimic the function of lost photoreceptors by reactivating preserved retinal circuitry. The compounds demonstrated preliminary safety profiles and restored visual function in zebrafish and mouse models of blindness caused by retinal degeneration. 1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in